Sciety

TIRmed Pharma AB is a Swedish company based in Bromma, founded in 2018. The firm specializes in developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroid cream designed to reduce inflammation and alleviate itching associated with the condition. The company focuses on addressing significant clinical needs through its innovative drug candidates.

PeptiSystems specializes in the manufacturing and supply of instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics. The company develops medical instruments that facilitate the production of peptides, which are essential for creating bioactive molecules used in various drugs. These peptides play a crucial role in the treatment of diseases, including AIDS, HIV, and diabetes, thereby assisting healthcare professionals in their efforts to address these significant health challenges.

TIRmed Pharma AB is a Swedish company based in Bromma, founded in 2018. The firm specializes in developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroid cream designed to reduce inflammation and alleviate itching associated with the condition. The company focuses on addressing significant clinical needs through its innovative drug candidates.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Encare AB, founded in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance perioperative care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company provides an interactive platform that enables surgical clinics to collect, document, and analyze performance data, facilitating improved patient recovery times and overall health outcomes. Encare's software includes components such as an ERAS protocol system, an audit system for surgeries, and tools for comparing outcomes, all aimed at delivering evidence-based best practices in surgical care. With rights to commercialize protocols developed by the ERAS Society, Encare has successfully deployed its solutions in over 120 hospitals across multiple countries, including Canada, several European nations, and the United States, thereby contributing to significant improvements in efficiency and quality of care in surgical settings.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Akiram Therapeutics is a Swedish biotech company specializing in targeted radioimmunotherapy for cancer treatment. The company leverages a proprietary antibody that targets the cancer marker CD44v6, combined with a radiation component, to create therapies that have demonstrated strong preclinical results in models of cancers lacking effective treatments. Akiram Therapeutics aims to develop novel radioactive molecules and pharmaceuticals that enhance the visualization and treatment of aggressive solid tumors. Its research focuses on significant indications, including head and neck cancer, acute myeloid leukemia, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, the company is composed of experts in radiation science, cancer precision medicine, and drug development, dedicated to advancing innovative therapeutic solutions in oncology.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

Encare AB, founded in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance perioperative care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company provides an interactive platform that enables surgical clinics to collect, document, and analyze performance data, facilitating improved patient recovery times and overall health outcomes. Encare's software includes components such as an ERAS protocol system, an audit system for surgeries, and tools for comparing outcomes, all aimed at delivering evidence-based best practices in surgical care. With rights to commercialize protocols developed by the ERAS Society, Encare has successfully deployed its solutions in over 120 hospitals across multiple countries, including Canada, several European nations, and the United States, thereby contributing to significant improvements in efficiency and quality of care in surgical settings.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.

Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.

Cavis Technologies is a start-up focused on developing healthcare devices aimed at diagnosing cardiovascular diseases. The company provides a unique device designed for invasive cardiology care units, enhancing control and safety during medical procedures. Its innovative device features a simple and robust design, utilizing a strategically positioned pressure sensor that minimizes hydrostatic error. This technology allows for effective assessment of the severity of narrowings in coronary arteries and myocardial disease, ultimately benefiting patients, cardiologists, and healthcare providers by improving diagnostic accuracy and patient outcomes.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Predicare AB, established in 2010 and based in Gothenburg, Sweden, specializes in developing decision support systems for the healthcare sector. Its primary product, the RETTS system, is designed to enhance emergency care by facilitating rapid triage and treatment through the assessment of vital parameters and the collection of structured medical histories. This clinical decision support tool aids healthcare professionals in making informed and timely decisions for a diverse range of patients, including adults, children, pregnant women, and those facing psychiatric emergencies. By streamlining the evaluation process, Predicare aims to improve the quality of care provided in emergency situations.

Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.

Single Technologies AB is a Stockholm-based company founded in 2012 that specializes in advanced imaging technology for applications in research, drug discovery, and diagnostics. The company has developed a novel single-molecule-sensitive 3D sequencing system that allows for high-throughput and cost-effective DNA reading. This technology leverages a combination of single-molecule imaging, large-area confocal scanning, and nanotechnology to provide precise genomic data. By enabling accurate diagnostics and personalized treatments, Single Technologies aims to enhance the capabilities of the healthcare industry through its innovative solutions in genomics and sequencing.

Athera Biotechnologies AB is a biopharmaceutical company based in Stockholm, Sweden, dedicated to developing targeted anti-inflammatory therapies and companion diagnostics for cardiovascular diseases (CVD). Founded in 2002, the company focuses on identifying immunological markers associated with atherosclerosis to enhance prevention and treatment strategies for CVD. Its product portfolio includes CVDefine, an immunological marker and ELISA kit designed for cardiovascular risk assessment, as well as innovative biopharmaceuticals like Annexin A5, which aims to prevent plaque rupture, and PC-mAb, a monoclonal antibody therapy targeting the uptake of oxidized LDL in macrophages. Athera's development efforts are grounded in research from the Karolinska Institutet and aim to meet the significant unmet medical needs in anti-inflammatory therapeutics for vascular diseases.

Likvor AB is a medical device company based in Umeå, Sweden, specializing in systems for neurological investigations. Founded in 2007, the company has developed the CELDA System, which assesses cerebrospinal fluid (CSF) dynamics, essential for diagnosing conditions such as Normal Pressure Hydrocephalus (NPH). The CELDA System, which includes an instrument, software, tool set, and a specialized examination bed, was CE-marked and made available to the market in 2009. This innovative system is based on nearly 40 years of research conducted at Umeå University and Umeå University Hospital. Likvor AB is certified according to ISO-13485 and is committed to advancing methods and devices related to CSF dynamics in collaboration with academic researchers. The CELDA System is available in multiple languages, enhancing its accessibility for healthcare providers.

Lipigon Pharmaceuticals AB is a biopharmaceutical company based in Umeå, Sweden, that specializes in the development of therapeutics for dyslipidemia and metabolic diseases. Founded in 2010, the company focuses on innovative treatments targeting lipoprotein lipase (LPL), an enzyme crucial for fat metabolism. Lipigon aims to address conditions related to low LPL activity, such as elevated blood fats, insulin resistance, and metabolic syndrome. The company's portfolio includes treatments for rare diseases like lipodystrophy and homozygous familial hypercholesterolemia, where existing therapies are insufficient. Lipigon has entered into a collaboration with AstraZeneca to further develop LPL-based pharmaceuticals, potentially receiving significant financial support as milestones in development and sales are achieved.

Cartana AB is a biotechnology company based in Solna, Sweden, specializing in mapping gene expression in brain tissue through In Situ Sequencing (ISS). Founded in 2017, Cartana's innovative technology allows for the simultaneous analysis of hundreds of genes within individual cells while preserving tissue morphology. This capability is essential for advancing research and biomarker discovery, treatment validation, and the development of future diagnostic tools. The company's flagship product, NeuroKit: Brain Cell Mapping, can identify over 100 genes in a single tissue section. Cartana also provides sequencing services that include sample preparation and analysis, facilitating deeper understanding of brain functions and diseases as well as tumors and other organs. As of August 2020, Cartana operates as a subsidiary of 10x Genomics, Inc.

Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.

PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.

Medpro Clinic Group is a healthcare provider based in Sweden, operating six innovative care centers in the Västra Götaland region. The company offers a diverse range of medical services, including primary care, rehabilitation, vaccinations, dermatology, cardiology, and drug rehabilitation. Medpro Clinic Group is dedicated to delivering high-quality care with a personal touch, facilitated by a passionate and committed staff. By focusing on accessibility and continuity of care, the organization aims to meet the diverse healthcare needs of its patients effectively.

Liv Diagnostics AB, founded in 2016 and based in Mölndal, Sweden, specializes in developing diagnostic tools that analyze tumor cells to assess the risk of metastasis. The company's innovative approach focuses on direct analysis of cancer cell behavior, contrasting with traditional indirect diagnostic methods. By mimicking the natural environment of cells within the human body, Liv Diagnostics enables physicians to directly observe the behavior of living cancer cells. Their product, CellRACE, quantifies the migration capacity of these cells, providing critical predictive information about metastasis risk. Liv Diagnostics operates as a subsidiary of Cline Scientific AB.

Raytelligence AB, a subsidiary of Swedish Adrenaline founded in 2015, specializes in developing microwave sensors for the healthcare and industrial markets. The company focuses on vital sign monitoring, offering products such as the RayVS1 sensor, which is capable of monitoring heartbeat, movement, and body position. Raytelligence's innovative solutions include cloud-based signal processing and analysis services, facilitating home monitoring for users. The company has received recognition for its advancements, including a grant from the Swedish Innovation Bureau to support the development of its radar sensor technology. Since its inception, Raytelligence has successfully certified its sensor for home use and established partnerships for sensor development in various applications, including the road construction industry and e-Health initiatives. The team at Raytelligence combines expertise in industrial design and radar signal processing, positioning the company as a key player in the sensor technology sector.

1928 Diagnostics is a digital health company that specializes in bioinformatics, focusing on the analysis of genomic data to combat antibiotic resistance. The company provides a cloud-based platform designed to assist microbiologists in utilizing their sequencing data effectively. Its software service facilitates outbreak tracing and diagnostics, enabling healthcare providers to implement comprehensive infection control measures. By offering a user-friendly, fast, and secure service, 1928 Diagnostics supports customers across healthcare, food, and environmental sectors in tracking and minimizing the spread of bacteria, viruses, and fungi on a global scale.

MedFilm specializes in providing animated films to enhance patient understanding of surgical interventions. The company develops a platform that offers 3D animated patient films in over a dozen languages, aimed at improving patient confidence and participation in their healthcare. These films are utilized in hospitals across Scandinavia, where they are accessible to patients upon admission and upon waking after surgery. Additionally, the films are displayed in waiting rooms and are available online for patients at home. By simplifying complex medical information, MedFilm assists healthcare providers in communicating effectively with patients, ultimately contributing to improved patient care.

PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.

Inhalation Sciences specializes in developing and commercializing advanced laboratory instruments for inhalation research. The company's flagship product, PreciseInhale, is a patented aerosol generation platform that facilitates the delivery of respirable dry powder aerosols, supporting drug development from preclinical studies to human clinical trials. This innovative system operates on a one-animal-at-a-time basis, requiring only milligrams of test substances, which significantly reduces costs and accelerates timelines for pharmacokinetic studies. Additionally, PreciseInhale provides high-resolution lung data with typically less than 10% standard deviation. Inhalation Sciences also offers the LaminarPace tool, designed for drying small amounts of drug substances. The company conducts contract research for both novel and generic inhalation drug developers, as well as for toxicology and environmental research institutes and academic institutions in the field of inhalation and aerosolization.

Learning to Sleep AB is a digital care provider based in Malmo, Sweden, specializing in evidence-based improvement programs for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary products: "Improve my Sleep," aimed at those with minor sleep issues requiring slight adjustments, and "Learning to Sleep," designed for individuals with more severe conditions to help restore their sleep memory. These clinically proven programs are accessible through web and mobile platforms, allowing users to engage with the treatment conveniently. Learning to Sleep has successfully assisted over 40,000 individuals, fostering a strong connection between patients and their psychologists through its unique business model.

Attana AB, founded in 2002 and based in Stockholm, Sweden, specializes in providing biologically relevant information that enhances the efficiency and performance of pharmaceutical drug development. The company develops third-generation analytical biosensor instruments that automate the analysis of molecular interactions with cells and tissues. These biosensors are utilized to determine binding characteristics, such as specificity, kinetics, and affinity of various biomolecules, including cells, antibodies, proteins, viruses, and bacteria. Attana serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies in Europe and Asia, and its technology has received validation from multiple reputable organizations in the field. The company also offers contract research services to further support the drug development process.